Navigation Links
Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
Date:12/8/2008

Designed to ensure comfort and optimize nutrition for women and their babies

SAN ANTONIO, Dec. 8 /PRNewswire/ -- Mission Pharmacal today announced the addition of CitraNatal(R) Assure to its CitraNatal(R) family of prescription prenatal vitamins. CitraNatal Assure builds on the benefits of the CitraNatal line and offers increased nutrients for women and their babies.

Prenatal vitamins are an important resource for women who are pregnant or planning to become pregnant. They provide women with the essential vitamins and minerals they may be lacking from a healthy diet alone.

"CitraNatal Assure provides women with all the prenatal essentials of the CitraNatal line, and also offers increased levels of several vitamins and minerals," said Neill Walsdorf, Jr., President of Mission Pharmacal. "Mission Pharmacal is proud to add this unique formulation to the CitraNatal family to offer women another prenatal option to meet their individual needs."

CitraNatal Assure contains 300mg of Martek's life'sDHA(TM), a patented, plant-based form of the omega-3 fatty acid DHA, which is consistent with current published guidelines for pregnant and lactating women(1). DHA is the recommended essential fatty acid for prenatal care. It has been shown to be instrumental in the baby's pre- and postnatal brain, eye and nervous system development, increase the baby's gestation period, birth weight and size, lead to higher visual acuity at age 60 days, and increase cognitive and psychomotor developments(2,3,4). DHA cannot be produced naturally by the body; it must be gathered from diet or supplements.

CitraNatal Assure also offers increased levels of iron and vitamin B6. Vitamin B6 contributes to a baby's developing brain and nervous system(5) and may help some women reduce severe nausea or vomiting during pregnancy(6). It also helps the body maintain blood glucose levels, meta
'/>"/>

SOURCE Mission Pharmacal Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
2. Alfacell Provides ONCONASE(R) NDA Submission Update
3. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
4. Joint Commission Urges Patients to Speak Up About Pain
5. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
6. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
7. Oregon Tourism Commission Unveils New Online Customer Service Training Program
8. FDA Reviewing Biomoda Submission for Cancer Screening Study
9. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
11. Patients Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, today ... 28, 2015. Net sales for the first ... 1.4% compared with the first quarter of 2014.  This ... 6.0% decline related to foreign currency exchange.  In local ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17
... overall survival rate from,cancer now is lower in older ... in part because of a lack of access to ... a study by pediatric,oncologists at Children,s Hospital of Pittsburgh ... than 15 with cancer have,improved dramatically over the last ...
... Period -, EXTON, Pa., Jan. 15 ... been completed in the pivotal,Phase III multi-center, double-blind, ... the treatment of,nasolabial folds, or wrinkles (Studies IT-A-005 ... of the study., Isolagen also announced the ...
Cached Medicine Technology:Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 2Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 3Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Morganville, NJ (PRWEB) May 04, 2015 ... that he has been chosen to receive the America’s ... Board. Dr. Champagne’s selection as a top dentist ... his commitment to continuing education and his compassion for ... Board selects professionals who exemplify excellence in their field. ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... The Accreditation for Cardiovascular ... congenital heart disease (CHD) standards for Pediatric ... Driven by the latest available clinical evidence, ... of interventional procedures in pediatric patients and ... ACE CHD Standards for PCCL Accreditation, like ...
(Date:5/4/2015)... May 04, 2015 Sara Soulati, CEO ... practice management firm in Los Angeles associated with the ... patent-pending status of The Sara Soulati Health For Life ... 2010, is a lifestyle modification and disease prevention program. ... to the U. S. Patents and Trademarks Office and ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... are a valuable tool for controlling infectious diseases ... Routine immunizations and supplemental immunization activities, such as ... to entire populations. Current measurements used to determine ... flawed and inconsistent. According to a new study ...
... announces a partnership with the U.S. Food and Drug ... Center of Excellence in Regulatory Science and Innovation (CERSI). ... an initial $1 million grant, which is potentially part ... and manufacturing. Experts in science, medicine ...
... more rapid innovation in science and technology, Peter Thiel ... Breakout Labs. Speaking at Stanford to an event ... Thiel announced that Breakout Labs will use a revolving ... research is funded by helping independent scientists and early-stage ...
... building blocks of proteins, are essential to support the ... An insufficient supply of amino acids in the mother,s ... developmental abnormalities and complications of pregnancy that result in ... cutting-edge article in the peer-reviewed journal Cellular Reprogramming ...
... , WEDNESDAY, Oct. 26 (HealthDay News) -- People ... attempt to boost their social status, a new study suggests. ... portions with higher social standing. For example, study participants believed ... social status than those who chose a medium or small ...
... New research has the potential to revolutionize the treatment ... a million Canadians which is expected to strike even more ... AF is the most common type of heart arrhythmia ... greater risk for stroke. Now, there is a new drug ...
Cached Medicine News:Health News:Researchers develop method to better estimate vaccine coverage 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 3Health News:Peter Thiel announces Breakout Labs to energize innovation 2Health News:Inadequate supply of protein building blocks may explain pregnancy failures in bovine cloning experiments 2Health News:Larger Food Portions May Be Seen as Status Symbols 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 3
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: